MedPath

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Phase 3
Completed
Conditions
Epilepsy
Interventions
Registration Number
NCT01339559
Lead Sponsor
UCB BIOSCIENCES, Inc.
Brief Summary

This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).

Detailed Description

The primary objective is to evaluate the long term safety and tolerability of BRV at individualized doses up to a maximum of 200 mg/day in epilepsy subjects.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
767
Inclusion Criteria
  • Subject completed the Treatment Period of N01358 or the evaluation period of N01258
  • Male/female subject from 16 years or older. Subject under 18 years may only be included where legally permitted and ethically accepted
  • Subject for whom the Investigator believes a reasonable benefit from the long term administration of BRV may be expected
  • Female subject without childbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible
Exclusion Criteria
  • Subject has developed hypersensitivity to any components of the investigational medicinal product (IMP) or comparative drugs as stated in this protocol during the course of the core studies
  • Severe medical, neurological, or psychiatric disorders, or laboratory values which may have an impact on the safety of the subject
  • Poor compliance with the visit schedule or medication intake in the previous BRV study
  • Planned participation in any other clinical study of another investigational drug or device during this study
  • Pregnant or lactating woman
  • Any medical condition which, in the Investigator's opinion, warrants exclusion
  • Subject has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
BrivaracetamBrivaracetamBrivaracetam with a maximum of 200 mg/day
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)From Entry Visit (Month 0) until the Last Visit (up to 84 months)

Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.

Percentage of Participants Who Withdrew Due to Adverse Events (AEs)From Entry Visit (Month 0) until the Last Visit (up to 84 months)

An AE is any untoward medical occurrence in a participant or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.

Percentage of Participants With at Least One Serious Adverse Event (SAE)From Entry Visit (Month 0) until the Last Visit (up to 84 months)

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:

* Results in death

* Is life-threatening

* Requires in patient hospitalization or prolongation of existing hospitalization

* Is a congenital anomaly or birth defect

* Is as infection that requires treatment parenteral antibiotics

* Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.

Secondary Outcome Measures
NameTimeMethod
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation PeriodFrom Baseline of the previous study until the Last Visit (up to 84 months)

The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as:

(the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines.

Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of percent change in POS frequency.

Responder Rate in POS (Type I) Frequency Over the Evaluation PeriodFrom Baseline of the previous study until the Last Visit (up to 84 months)

A responder is defined as a subject with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study.

Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of responder rates in POS frequency.

Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation PeriodFrom Baseline of the previous study until the Last Visit (up to 84 months)

The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28.

Trial Locations

Locations (184)

064

🇺🇸

Port Charlotte, Florida, United States

011

🇺🇸

Dallas, Texas, United States

778

🇺🇸

Columbus, Ohio, United States

070

🇺🇸

Columbus, Ohio, United States

071

🇺🇸

Miami, Florida, United States

701

🇭🇰

Hong Kong, Hong Kong

411

🇭🇺

Budapest, Hungary

731

🇮🇳

Nashik, Maharashtra, India

126

🇲🇽

Guadalajara, Jalisco, Mexico

627

🇱🇻

Daugavpils, Latvia

425

🇱🇹

Alytus, Lithuania

426

🇱🇹

Vilnius, Lithuania

129

🇲🇽

Aguascalientes, Mexico

412

🇭🇺

Budapest, Hungary

726

🇮🇳

Bangalore, India

852

🇯🇵

Itami, Hyogo, Japan

403

🇳🇱

Zwolle, Netherlands

006

🇺🇸

Tucson, Arizona, United States

077

🇨🇦

Greenfield Park, Quebec, Canada

650

🇪🇪

Tallinn, Estonia

477

🇵🇱

Poznan, Poland

501

🇷🇺

Kazan, Russian Federation

508

🇷🇺

Smolensk, Russian Federation

101

🇧🇷

Sao Paulo, Brazil

005

🇺🇸

Peoria, Illinois, United States

009

🇺🇸

Golden Valley, Minnesota, United States

042

🇺🇸

Hamilton, New Jersey, United States

017

🇺🇸

Winfield, Illinois, United States

023

🇺🇸

Atlanta, Georgia, United States

029

🇺🇸

Chicago, Illinois, United States

775

🇺🇸

Little Rock, Arkansas, United States

039

🇺🇸

Boise, Idaho, United States

048

🇺🇸

Rome, Georgia, United States

022

🇺🇸

New York, New York, United States

078

🇨🇦

London, Ontario, Canada

294

🇧🇬

Blagoevgrad, Bulgaria

035

🇺🇸

Dallas, Texas, United States

076

🇨🇦

Toronto, Ontario, Canada

301

🇫🇷

Bethune, France

335

🇩🇪

Muenchen, Germany

328

🇩🇪

Ulm, Germany

251

🇨🇿

Ostrava, Czechia

902

🇩🇪

Erlangen, Germany

201

🇦🇹

Linz, Austria

275

🇫🇮

Kuopio, Finland

100

🇧🇷

Florianopolis, Brazil

777

🇺🇸

Dallas, Texas, United States

916

🇨🇿

Kromeriz, Czechia

331

🇩🇪

Göttingen, Germany

015

🇺🇸

Philadelphia, Pennsylvania, United States

286

🇧🇬

Sofia, Bulgaria

652

🇪🇪

Tallinn, Estonia

651

🇪🇪

Tartu, Estonia

384

🇮🇹

Reggio Calabria, Italy

079

🇨🇦

Montreal, Canada

104

🇧🇷

Belo Horizonte, Brazil

256

🇨🇿

Ostrava, Czechia

054

🇺🇸

Tulsa, Oklahoma, United States

252

🇨🇿

Praha 1, Czechia

327

🇩🇪

Kiel, Germany

380

🇮🇹

Firenze, Italy

376

🇮🇹

Perugia, Italy

227

🇧🇪

Leuven, Belgium

287

🇧🇬

Sofia, Bulgaria

332

🇩🇪

Bielefeld, Germany

334

🇩🇪

Osnabruck, Germany

917

🇨🇿

Brno, Czechia

253

🇨🇿

Praha 4, Czechia

250

🇨🇿

Zlin, Czechia

377

🇮🇹

Monserrato, Italy

386

🇮🇹

Napoli, Italy

750

🇰🇷

Seoul, Korea, Republic of

528

🇪🇸

Barcelona, Spain

330

🇩🇪

Ravensburg, Germany

900

🇩🇪

Marburg, Germany

379

🇮🇹

Milano, Italy

729

🇮🇳

Madurai, India

375

🇮🇹

Pisa, Italy

607

🇬🇧

Newcastle, United Kingdom

753

🇰🇷

Busan, Korea, Republic of

526

🇪🇸

Valladolid, Spain

725

🇮🇳

Mumbai, India

130

🇲🇽

Mexico City, Mexico

378

🇮🇹

Bari, Italy

751

🇰🇷

Seoul, Korea, Republic of

754

🇰🇷

Seoul, Korea, Republic of

854

🇯🇵

Yokohama-City, Japan

125

🇲🇽

Distrito Federal, Mexico

629

🇱🇻

Jekabpils, Latvia

628

🇱🇻

Riga, Latvia

485

🇵🇱

Gdansk, Poland

793

🇵🇱

Krakow, Poland

483

🇵🇱

Lublin, Poland

795

🇵🇱

Katowice, Poland

540

🇪🇸

Barcelona, Spain

503

🇷🇺

Moscow, Russian Federation

529

🇪🇸

Barcelona, Spain

535

🇪🇸

Barcelona, Spain

800

🇨🇳

Tainan, Taiwan

600

🇬🇧

London, United Kingdom

551

🇸🇪

Goteborg, Sweden

552

🇸🇪

Linkoping, Sweden

539

🇪🇸

San Sebastian, Spain

532

🇪🇸

Santiago de Compostela, Spain

602

🇬🇧

Morriston, Swansea, United Kingdom

806

🇨🇳

Kaohsiung City, Taiwan

537

🇪🇸

Valencia, Spain

801

🇨🇳

Taichung, Taiwan

803

🇨🇳

Taoyuan, Taiwan

601

🇬🇧

Truro, United Kingdom

605

🇬🇧

Middlesborough, United Kingdom

034

🇺🇸

Cleveland, Ohio, United States

020

🇺🇸

Ames, Iowa, United States

098

🇺🇸

Poughkeepsie, New York, United States

069

🇺🇸

Iowa City, Iowa, United States

002

🇺🇸

Toledo, Ohio, United States

049

🇺🇸

Houston, Texas, United States

043

🇺🇸

Oklahoma City, Oklahoma, United States

001

🇺🇸

Phoenix, Arizona, United States

008

🇺🇸

Bethesda, Maryland, United States

013

🇺🇸

Phoenix, Arizona, United States

060

🇺🇸

Aurora, Colorado, United States

025

🇺🇸

San Francisco, California, United States

776

🇺🇸

Nashville, Tennessee, United States

003

🇺🇸

Durham, North Carolina, United States

091

🇺🇸

Oklahoma City, Oklahoma, United States

057

🇺🇸

Milwaukee, Wisconsin, United States

036

🇺🇸

Charlottesville, Virginia, United States

068

🇺🇸

Waldorf, Maryland, United States

032

🇺🇸

Lebanon, New Hampshire, United States

099

🇺🇸

New York, New York, United States

010

🇺🇸

Asheville, North Carolina, United States

050

🇺🇸

Mansfield, Texas, United States

913

🇨🇿

Ostrava Poruba, Czechia

329

🇩🇪

Berlin, Germany

305

🇫🇷

Montpellier, France

326

🇩🇪

Bernau, Germany

727

🇮🇳

Hyderabad, India

855

🇯🇵

Hiroshima, Japan

383

🇮🇹

Pozzilli, Italy

127

🇲🇽

Culiacan, Mexico

128

🇲🇽

Guadalajara, Jalisco, Mexico

400

🇳🇱

Heeze, Netherlands

475

🇵🇱

Bialystok, Poland

038

🇵🇷

San Juan, Puerto Rico

480

🇵🇱

Katowice, Poland

476

🇵🇱

Krakow, Poland

481

🇵🇱

Katowice, Poland

791

🇵🇱

Gdansk, Poland

478

🇵🇱

Katowice, Poland

794

🇵🇱

Warszawa, Poland

527

🇪🇸

Valencia, Spain

550

🇸🇪

Stockholm, Sweden

603

🇬🇧

Birmingham, United Kingdom

608

🇬🇧

Salford, United Kingdom

276

🇫🇮

Tampere, Finland

202

🇦🇹

Innsbruck, Austria

851

🇯🇵

Shizuoka, Japan

625

🇱🇻

Valmiera, Latvia

427

🇱🇹

Kaunas, Lithuania

027

🇺🇸

Orlando, Florida, United States

075

🇨🇦

Calgary, Alberta, Canada

226

🇧🇪

Hechtel-Eksel, Belgium

413

🇭🇺

Szekszard, Hungary

728

🇮🇳

Mumbai, India

203

🇦🇹

Wien, Austria

414

🇭🇺

Hajdú-Bihar, Hungary

850

🇯🇵

Osaka, Japan

479

🇵🇱

Poznan, Poland

509

🇷🇺

Nizhny Novgorod, Russian Federation

021

🇺🇸

Port Royal, South Carolina, United States

028

🇺🇸

Charleston, South Carolina, United States

080

🇨🇦

Saskatoon, Saskatchewan, Canada

410

🇭🇺

Budapest, Hungary

502

🇷🇺

Moscow, Russian Federation

401

🇳🇱

Heemstede, Netherlands

482

🇵🇱

Poznan, Poland

488

🇵🇱

Warszawa, Poland

506

🇷🇺

Kazan, Russian Federation

061

🇺🇸

Austin, Texas, United States

780

🇺🇸

Lexington, Kentucky, United States

052

🇺🇸

Madison, Wisconsin, United States

056

🇺🇸

Spokane, Washington, United States

700

🇭🇰

Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath